All right. Thank you. Happy to be on this panel with Heather Turner, CEO of LB Pharmaceuticals. We'll keep it conversational, but maybe I'll just pass it over to Heather to give a quick update on the company. I know it can't be that quick because you have five programs for this drug, but you got 30 seconds, so go.
Great. Where we sit today is quite different than where we were a year ago when we went public last September. LB-102 is our asset, and it is reading out phase III schizophrenia data in the first half of next year. We'll have bipolar depression data coming in 2028, and we'll have phase II adjunctive MDD data coming in 2029. We have very meaningful data coming over the next three years, and we have cash that takes us into and beyond the second quarter of 2029. All of those trials are funded. We've also funded all of the activities related to an NDA submission with respect to schizophrenia. This includes the open-label safety trial that we need to run, as well as all the NDA-enabling studies. We're well-positioned with a successful phase III trial to put ourselves in a position to submit an NDA.
Great. Well, yeah, maybe let's talk about the upcoming schizophrenia readout. You have some very strong phase II data. There's the amisulpride data. Maybe outside of that, do you want to just talk about the study design and all the little things you've done to risk mitigation there?
The phase III NOVA-2 trial is actually quite similar in size and scope to the phase II NOVA-1 trial. It's 25 sites in the U.S. We're targeting the enrollment of 460 patients. We are evaluating two doses in our NOVA-2 trial. It's 50 mg and 100 mg, which is a little bit different than the NOVA-1. NOVA-1 had three doses, so that's one way of mitigating the placebo rate is just reducing a dose arm. The other thing that we've done is we've extended the duration. The NOVA-2 trial is six weeks in duration inpatient. The NOVA-1 trial was four weeks in duration. When we look at the efficacy curves from the NOVA-1 trial, we think there's an opportunity to see some additional separation from placebo.
The other thing we've done is we've taken a number of measures to just continue to have that frequent, consistent oversight of the sites in the trial. One thing we've done is we've created an app where we can look at our data real-time. We can see any sort of deviations or outlier information or anything like that that allows us to get on top of that data really quickly, which in these trials is really important. That's been a nice change that we've taken. We, of course, have done all of the measures we did in NOVA-1 with NOVA-2 in terms of managing that placebo rate. We have vendors that help identify and exclude professional patients. We were very deliberate in the number of scales that we chose to include in this trial.
We know that both rater fatigue and patient fatigue are real contributors to placebo rates. All of those same measures that we did in NOVA-1, we're also doing in NOVA-2.
Okay, great. Do you want to maybe just kind of frame, given we're getting close to the top line now, like beyond hitting a P-value on the PANSS and knowing you can register the drug, what else would constitute a win here and increase your confidence overall in LB-102?
One of the most, I think, attractive attributes of LB-102 in schizophrenia is the balance that it could potentially provide. We see in the COBENFY launch, for example, that you need to have not just efficacy, you also need to have a tolerability and a simplicity of use that I think will enable patients to stay on the drug. For us, I think seeing a balanced profile in the NOVA-2 trial is going to be important. We want to see that competitive efficacy. We want to see that we'll treat the patients who are experiencing positive symptoms. Equally so, we want to see a tolerability profile which would enable these patients to stay on the drug. We know that there are certain adverse events that are big contributors to discontinuation, one of which is EPS.
If we continue to see a lower rate of EPS, we think that that's very attractive. One of the other things we saw in NOVA-1 that I think will be important in NOVA-2 is, do we see an effect early? We know that seeing an effect early is something that's really attractive to prescribers. In NOVA-1, we saw an effect as early as the first week of evaluation, and so we hope that we'll continue to see that. Then, we already know this, but simplicity of use continues to be important. We have once-daily dosing. There is no titration. We don't have a food effect, and so we think that that will continue to be important.
Okay, great. On the safety side more specifically, maybe just talk about what are the AEs that you think look better and differentiated from other drugs, and where are there still any outstanding questions in your mind?
Well, the one we just talked about is EPS. EPS is an adverse event that has been associated with antipsychotics since the very first antipsychotics. The fact that we saw a very low rate of EPS despite the fact that we're a D2 antagonist, despite the fact that we have 70% dopamine receptor occupancy, is, I think, something very differentiating. We had an R&D Day at the end of October where we presented some preclinical data that we believe provides a plausible mechanism as to why we have that low rate of EPS, and that is the fact that we actually do not hit the motor striatum nearly as much as other D2 antagonists. We think that that's a potential reason to believe that we'll continue to see a low rate of EPS. I think we saw a nice treatment-emergent adverse effect profile.
We didn't see anything there that we thought was unexpected or unusual. I think we're a D2 antagonist. We know we'll see increases in prolactin. I think one of the things that we'll continue to assess is just whether it's a lab value or whether it actually results in clinical manifestation. What we saw in our NOVA-1 trial was a very low rate of adverse events associated with that, and none of them led to discontinuation. It actually isn't an adverse event that often leads to discontinuation relative to others. We'll continue to look at that, but so far, what we've seen is a very, very low rate that results in adverse events associated with that, and none of them lead to discontinuation.
What is your level of confidence that if this study's positive, you have enough data to file in schizophrenia?
We had a robust engagement with FDA at the time of our end of phase II meeting. We designed NOVA-1 to be registrational. It was 359 patients. We had all of the sensitivity analyses that you would expect for a phase III trial, including the real conservative imputation for missing data, the one that's most punitive to LB-102. Coming out of that engagement, we asked FDA whether they considered that trial to be adequate and well-controlled, and they said that it had many of the characteristics of an adequate and well-controlled trial. We're highly confident in that trial being robust and being considered an adequate and well-controlled trial. If we have an equally robust NOVA-2 trial, we think that we're in a really good position.
Great. Maybe on the commercial side in schizophrenia, obviously there's a lot of talk about other atypicals having softer launches in schizophrenia. COBENFY sold a lot worse than it surveyed, at least for what it's worth on everything maybe surveys better than it sells. Just in the context of that, how do you think about tackling that market, and what gives you the confidence that LB-102 can still be commercially successful in schizophrenia?
Like I started with, I fundamentally believe that having a balanced profile is going to be critically important to prescribers. Efficacy is, of course, important. Confidence that you will have a medicine that'll treat these positive symptoms is, of course, important. Equally important is this ability to stay on the drug, and that, I think, is impacted by the tolerability profile as well as by the simplicity of use. I think that's part of the challenge with the COBENFY launch. The other aspect is the GI side effects. I think that many physicians are not taking their patient to the top dose that was actually studied in the phase III trials, and so they're sub-optimally dosed, and they're not seeing the efficacy that I think they anticipated.
The fact that we have no titration, patients start at a therapeutic dose, we do see an early effect, is, I think, very important to just continue to bring confidence to the prescribers. The other thing I will note is there is a lot of familiarity with D2 antagonists. These physicians are very familiar with prescribing and treating patients with D2 antagonists, and I actually think from a commercial perspective, that could be quite helpful, that there is already a familiarity. The other aspect is how do you use LB-102? I think making sure that when we do commercially launch, we can provide information to physicians about how to switch or how to add LB-102 onto their current treatment regimen is also going to be important.
Yeah. Okay. Makes sense. Maybe switching gears to mood disorders, do you want to review for people the evidence we have from amisulpride, and maybe what would you say to someone who says, "Okay, there is interesting evidence, but a lot of these are old studies. Some of them were not placebo-controlled. How much confidence can we have in it?
Yeah. When you look at the heritage of data around amisulpride, it has been studied quite extensively in, I will call them depressive-related disorders. So, amisulpride is one of the few antipsychotics that has shown in three randomized placebo-controlled trials to have a statistically significant effect on treating patients with predominantly negative symptoms of schizophrenia. Negative symptoms of schizophrenia is an area of significant unmet need. There is no approved treatment for it, and 60% of patients with schizophrenia suffer from predominantly negative symptoms, and it is characterized by highly depressive-like symptoms. So, anhedonia is a very big part of negative symptoms. amisulpride has also been studied against placebo in patients with major depressive disorder, and there, they had a statistically significant effect over placebo, a MADRS delta of 4.8. It has also been studied head-to-head against ZOLOFT and PAXIL, and there, it was as good or better than both of those.
There is actually quite a bit of clinical data. In addition to the clinical data, there is quite a bit of real-world data. When you look at the script data for amisulpride, in 2023, there were about 2 million prescriptions written, and 20% of those were used in mood disorders. So, it is actually quite extensively used in this space, so there is quite a bit of data out there. When we thought about the design of our trials and the doses to use in our trials, we actually looked to amisulpride.
Yeah, that was my next one.
One of the things we looked at was exactly what doses were used. We then looked at the dopamine receptor occupancy data, and we then modeled it to our own data that we have generated from our phase I trials and our PK trial and our NOVA-2 trial, and we used that to align as best we could to the amisulpride doses. So, where we ended up in bipolar depression is we're studying 25mg and 50mg , and where we ended up with major depressive disorder is we're studying 15mg and 25mg . The other area that we think is interesting and that we think is also a nice reason to believe is that the mechanism of LB-102 is similar to that of amisulpride in that at high doses, they operate to block dopamine, and at low doses, they actually operate to trigger the signaling of dopamine, right?
They trigger the release of dopamine. That's why you see this variation in dose in these trials, so that you're at your highest dose in schizophrenia and you're at your lowest dose in major depressive disorder. So, we basically tracked as best we could to what we think the most relevant data point.
There's a lot of data for amisulpride in MDD. There's less in bipolar. Does that make you more confident in MDD versus bipolar, or do you kind of look at this as sort of like it's behaving like an atypical that works in mood, so it should work in multiple different types of mood disorders?
Yeah, I actually don't think it changes whether or not it's going to be more or less likely. I think when you look biologically, whether it's unipolar depression or bipolar depression, the biology is the same. I think we have confidence coming out of our NOVA-1 trial that we should be able to control mania, which remember, in bipolar depression, these patients oscillate between depressive disorders and manic disorders, right? Part of what you need to do is prevent these patients from transitioning to mania.
Right.
I do think there's some evidence coming out of that NOVA-1 trial that we would do that.
Bipolar, we'll read out first, I think you've said first quarter of 2028. What would you see as a competitive and strong data set there?
It's interesting across all of the disorders that we're pursuing, there's a very common thesis, which is we think that efficacy in all of these disorders is sort of the ticket to entry. There's not a whole lot of difference in efficacy across the approved therapeutics. What it really boils down to is what is that tolerability profile and how does that impact patients? When you move from schizophrenia to bipolar disorder to major depressive disorder, you actually are increasing in function. These patients are more and more functional. Some of these adverse events that really impact function, like EPS, like sedation, are things that have become more meaningful to these patients. We hope to have a very competitive efficacy profile in both of these mood disorder indications and a tolerability profile that can really allow these patients to continue to take their drug.
On top of that, I think there are two areas where we could be quite differentiated. The first is in cognition. Across all these disorders, these patients experience some form of cognitive impairment, more so in schizophrenia, but they all experience some form of cognitive impairment. What we observed in our NOVA-1 trial was a dose-dependent, highly statistically significant response on the cognition scale that we utilized in that NOVA-1 trial. In both bipolar depression and adjunctive MDD, we are assessing cognition as a secondary endpoint in both those trials. If we continue to see a benefit there, that could be something quite differentiating. The other is what we have already talked about, which is anhedonia. Across all of these disorders, patients continue to experience anhedonia as a residual symptom. We are there also prospectively looking at specific anhedonia scales.
If you do see a benefit there, that also would be highly differentiating.
Makes sense. Anything else to add on the mood disorder side, or should we talk about some of the other indications?
Just with respect to the mood disorders, we think that the other interesting aspect of this is just that early onset of response. That is something else that I think will be important to physicians as well, that they see an effect pretty quickly.
Okay. Makes sense. On negative symptoms, I think most folks who do investing in CNS know that it's a super tough indication. The FDA doesn't make it easy by pushing sponsors towards targeting patients that have stable positive symptoms. So, in the context of that, maybe talk one, what drives your optimism there, and maybe some of the older amisulpride data, like how strong is that? Then just two, how do you think about the path to potential registration there?
The older amisulpride data does lend quite a bit of confidence. amisulpride, I mentioned, was studied in three randomized placebo-controlled trials in patients with predominantly negative symptoms. So, it is in this stabilized patient population that you note. It was studied at different durations. So, it was studied at 12 weeks, 16 weeks, six months. In all three of those clinical trials, it showed statistically significant benefit over placebo. It actually has an indication for negative symptoms in some jurisdictions. So, it's considered highly robust data set. I think that's very helpful data point. The other is in our NOVA-1 trial, at our lowest dose, 50mg , on the PANSS negative symptom subscale, we did see a statistically significant benefit.
Of course, that's not exactly in the right patient population, so you have to take it with a grain of salt, but I do think it's a helpful data point. I think it is a notoriously tough space, but if there is a therapeutic that's got potential to show some benefit here, I think LB-102 would be it.
Do you look at the study that Minerva's doing as like an analog, or are there differences?
I think Minerva's a very different molecule, predominantly because they haven't actually demonstrated any efficacy in psychosis. Their trial design is very different because of that. Because we will already have data in schizophrenia, I think it'll be pretty clear that the risk of relapse with our patients will be less. So that isn't something that we'll have to be demonstrating
Right
in the trial.
But maybe like the parallel group portion of their study-
Potentially, right.
would be a reasonable
I mean, we know FDA has a preference for placebo-
Right
versus an active comparator.
Right.
We know that that will likely be the case. Duration is an interesting question that we are still working to align on. There are certain questions around that trial design that I think will be important to align with FDA on. But I would say some of the trial will be similar, but a lot of it will be different too.
Yep. Okay. For Alzheimer's, you've talked about your aspirations there, going to do a healthy elderly study. How are you weighing the best way to bring a drug to market for Alzheimer's?
Yeah. The good news is, we'll have some time to see how this market plays a little bit. We'll see some data from the muscarinics, which I think will be important to see. We'll see how the AUVELITY launch continues to go. It's early days on that launch. We'll start to see, there's a couple of other therapeutics that are being evaluated in this space. So I think we'll have a lot to learn while we're conducting this healthy elderly volunteer study. The other thing we're doing is quite a bit of market research. We're looking at the profile of what we believe LB-102 will be. We're going to look at how that might be in both psychosis as well as agitation. So over the next, call it six to 12 months, we'll learn a lot about where we should direct it.
Look, if money were no object, we'd go into both. So maybe that'll be, I don't know. Hopefully, we'll see if that becomes an object.
That would be cool. How are you running this healthy elderly study, and how might the results of that be communicated to people like us?
Yeah. It's a phase I trial, right? The objective of that is to demonstrate safety, first and foremost, in this elderly population. We'll, of course, look at PK too, to see how we might need to adjust the dose. But those will be the two things that we'll need to do. To us, we're not anticipating anything coming out of that. That would be unusual. So it's going to be a check the box kind of exercise.
Right. Okay. Great. Anything else you want to touch upon? I just think before we wrap up, it's always good to hear just cash runway, and maybe you can review the timing of all the readouts one more time. But anything else you want to cover?
Right where we sit today is, I think we're very well positioned. We have a nice healthy balance sheet. We have cash that takes us beyond the second quarter of 2029, and we have three clinically meaningful data readouts over the next three years. So we've got the phase III schizophrenia data coming in the first half of next year. We've got the bipolar depression data coming in 2028, and then we have the adjunctive MDD data coming in 2029. And then beyond that, we'll have additional data in either negative symptoms or Alzheimer's disease, agitation, or psychosis. So we have quite a bit of really interesting, meaningful data coming over the next few years. And from a cash perspective, we're very well positioned to see these data readouts through.
Great. Awesome. Best of luck. Thanks, Heather.
Thank you so much.